On Friday, Restaurant Brands International Inc (NYSE:QSR)’s shares declined -2.88% to $39.43.
The BURGER KING® brand is owned by Restaurant Brands International Inc. (TSX,NYSE:QSR), BURGER KING® restaurants are introducing its spiciest product yet, new Fiery Chicken Fries. Accessible for a limited time only, Fiery Chicken Fries are made with the same white meat chicken as original Chicken Fries, flavored with a marinade of cayenne pepper, black pepper and other savory spices that will make your mouth cry.
BURGER KING® restaurants brought back Chicken Fries as a permanent menu item in March 2015 to satisfy the pleas of craving fans on social media. Since Chicken Fries fans are always open to bold, new adventures, and with over half of all Americans surveyed saying they prefer very spicy foods*, Fiery Chicken Fries were developed to create a flavor experience somewhere between pleasure and OM#G.
Restaurant Brands International Inc. owns and operates quick service restaurants under the Burger King and Tim Hortons brand names. As of February 17, 2015, it franchised or owned 19,043 restaurants in about 100 countries and U.S. territories worldwide. The company was founded in 1954 and is headquartered in Oakville, Canada.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s shares dropped -2.20% to $126.17.
BioMarin Pharmaceutical Inc. (BMRN) declared that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for drisapersen, a potential treatment for patients with Duchenne Muscular Dystrophy (DMD) who are amenable to exon 51 skipping treatment. The FDA has formerly granted drisapersen Orphan and Fast Track Status, Breakthrough Therapy Designation, in addition to Precedingity Review status, which is designated to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, counting drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally accessible poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis.
At the end of Friday’s trade, Commscope Holding Company Inc (NASDAQ:COMM)‘s shares dipped -4.15% to $29.31.
CommScope Holding Company, Inc., a global provider of connectivity and essential infrastructure solutions for wireless, business enterprise and residential broadband netoperates, plans to take part in the Jefferies Semiconductors, Hardware and Communications Infrastructure Summit on Tuesday, August 25.
CommScope Holding Company, Inc., together with its auxiliaries, provides connectivity and infrastructure solutions for wireless, business enterprise, and residential broadband netoperates worldwide. The company operates through three segments: Wireless, Enterprise, and Broadband. The Wireless segment offers macro cell site solutions primarily under the Andrew brand, counting base station antennas, microwave antennas, hybrid fiber-feeder and power cables, coaxial cables, connectors, amplifiers, filters, and backup power solutions; and small cell distributed antenna systems (DAS) solutions that allow wireless operators to enhance spectral efficiency, and cellular coverage and capacity in network conditions, such as commercial buildings, urban areas, stadiums, and transportation systems.
Incyte Corporation (NASDAQ:INCY), ended its Friday’s trading session with -2.99% loss, and closed at $104.31.
Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company focused on the discovery, development and commercialization of innovative proprietary therapeutics, recently declared it has been ranked 7th on Forbes magazine’s 2015 list of the World’s Most Innovative Companies.
Forbes’ ranking is based on the companies’ “innovation premium”, and only comprises industries that are known to invest in innovation and businesses that have at least seven years of financial data and a market value greater than $10 billion.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line comprises ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, in addition to INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
